Clinical trials: Heart Failure and Preserved Ejection Fraction
Anemia
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling…
- Trial name
- NCT00286182
- Testing
- Erythropoietin alpha
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mathew S. Maurer
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
- Trial name
- PANACHE (NCT03098979)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 76 sites in United States, Austria and 10 more
- Volunteers
- 305 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and…
- Trial name
- EMBARK-HFpEF (NCT04766892)
- Testing
- mavacamten
- Where
- 21 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure…
- Trial name
- NCT03037580
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 84 people
- Sponsor
- United Therapeutics
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Heart Failure, Diastolic
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT03133793
- Testing
- CoQ10, D-Ribose Oral Powder
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction
A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease.
- Trial name
- SERENADE (NCT03153111)
- Testing
- Macitentan
- Where
- 95 sites in United States, Argentina and 15 more
- Volunteers
- 143 people
- Sponsor
- Actelion
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Diastolic
External Body Pressure in Heart Failure With Preserved Ejection Fraction
The primary objective of the study is to test the impact of positive and negative body pressure on exercise capacity, symptoms, blood volume distribution and central cardiac hemodynamics in patients with heart failure and…
- Trial name
- NCT05764564
- Testing
- Positive or negative pressure
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Duke University
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Heart Failure
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries.
- Trial name
- SATELLITE (NCT03756285)
- Testing
- AZD4831
- Where
- 13 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Chronic Heart Failure With Preserved Systolic Function
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart…
- Trial name
- PRESERVED-HF (NCT03030235)
- Testing
- Dapagliflozin 10Mg Oral Tablet
- Where
- 26 sites in United States
- Volunteers
- 324 people
- Sponsor
- Saint Luke's Health System
Heart Failure, Diastolic, Obesity
Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)
The purpose of this study is to examine the effects of weight loss via hypocaloric diet (CR)and aerobic exercise (AT) compared to the effects of weight loss via hypocaloric diet (CR), aerobic training (AT)and resistance training…
- Trial name
- SECRET-II (NCT02636439)
- Testing
- dietary, aerobic and resistance training, dietary, and aerobic exercise
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Wake Forest University Health Sciences
Heart Failure With Preserved Ejection Fraction
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF…
- Trial name
- PARALLAX (NCT03066804)
- Testing
- sacubitril/valsartan, Enalapril, Valsartan
- Where
- 380 sites in United States, Argentina and 30 more
- Volunteers
- 2,572 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction
This will be a randomized, double-blind, crossover pilot study to measure the safety and feasibility of Interleukin-1 (IL-1) blockade with Anakinra in patients with stable heart failure with preserved ejection fraction.
- Trial name
- NCT01542502
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Commonwealth University
Aging, Heart Failure With Preserved Ejection Fraction
Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage…
- Conditions
- Aging, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Frailty
- Trial name
- RETRO (NCT06576297)
- Testing
- Inspiratory Muscle Training (IMT), Standard of Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pittsburgh
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases, Heart Diseases
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
- Trial name
- TOPCAT (NCT00094302)
- Testing
- Spironolactone
- Where
- 270 sites in United States, Argentina and 4 more
- Volunteers
- 3,445 people
- Sponsor
- Carelon Research
Chronic Heart Failure With Preserved Ejection Fraction
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after…
- Trial name
- VITALITY-HFpEF (NCT03547583)
- Testing
- Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
- Where
- 177 sites in United States, Argentina and 19 more
- Volunteers
- 789 people
- Sponsor
- Bayer